Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
UK pharma group reprimands Novo Nordisk for undisclosed payments
ABPI noted that Novo Nordisk’s breach of its conduct was “extremely concerning” and issued a public reprimand. Image Credit: Kittyfly / Shutterstock. The Association of
July 8, 2024